Form 4: Aclaris Therapeutics Officer Reports Stock Transactions

Joseph Monahan, Chief Scientific Officer of Aclaris Therapeutics, reports multiple transactions involving common stock and restricted stock units.

Summary

• On March 1st and 2nd, 2024, Joseph Monahan, the Chief Scientific Officer of Aclaris Therapeutics, engaged in several transactions involving the company's common stock and restricted stock units.
• These transactions included the vesting and settlement of restricted stock units, as well as the withholding of shares by the issuer to satisfy tax obligations.
• Specifically, 50,000, 10,925 and 12,500 restricted stock units vested on March 1st and 2nd.
• The reporting person now directly owns 186,783 shares of common stock and indirectly owns 193 shares through a spouse.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• Employees may be interested in the stock transactions of the Chief Scientific Officer.

Key Dates